News

The £4m raise was co-led by Science Creates Ventures and Octopus Ventures alongside Jonathan Milner and previous and new angel investors. The funding will enable Imophoron to progress a new class of thermostable vaccines based on cutting edge synthetic biology. Its technology has the potential to revolutionise the vaccine industry by increasing the speed of development whilst simultaneously eliminating the cold chain, transforming both shelf-life and distribution.